Tan Kenneth, Lai Nai Ming, Sharma Ajay
Monash Newborn, Monash Medical Centre/Monash University, Clayton, Australia.
Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD008155. doi: 10.1002/14651858.CD008155.pub2.
Pulmonary surfactant is an important part of the host defence against respiratory infections. Bacterial pneumonia in late preterm or term newborn infants often leads to surfactant deficiency or dysfunction, as surfactant is either inactivated or peroxidated. Studies of animal models of pneumonia and clinical case reports suggest that exogenous surfactant might be beneficial to infants with bacterial pneumonia.
To assess the effect of exogenous surfactant treatment on mortality and pulmonary complications in infants with bacterial pneumonia.
We used standard Cochrane Collaboration methodology to conduct our search of databases. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 6); MEDLINE (accessed via Ovid SP June 2011); EMBASE (via Ovid SP 1980 to June 2011); and CINAHL Plus (accessed via EBSCOHost June 2011).
We limited our search to randomised and quasi-randomised trials of surfactant replacement therapy in infants > 35 weeks gestation with bacterial pneumonia in the first 28 days of life. The primary outcome measures were death, time to resolution of pneumonia, incidence of chronic lung disease, pneumothoraces and pulmonary haemorrhage.
We assessed all studies with predefined criteria as to whether they were eligible for inclusion. We extracted data using RevMan 5 (RevMan 2011). We used the standard Cochrane Collaboration methodology for data collection and analysis to assess risk of bias, heterogeneity, treatment effect, missing data and reporting bias where appropriate.
We did not identify any studies that met our inclusion criteria.
AUTHORS' CONCLUSIONS: There is no evidence from randomised controlled trials (RCTs) to support or refute the efficacy of surfactant in near-term and term infants with proven or suspected bacterial pneumonia. RCTs are still required to answer this question.
肺表面活性物质是宿主抵御呼吸道感染的重要组成部分。晚期早产儿或足月儿的细菌性肺炎常导致表面活性物质缺乏或功能障碍,因为表面活性物质会被灭活或过氧化。对肺炎动物模型的研究和临床病例报告表明,外源性表面活性物质可能对患有细菌性肺炎的婴儿有益。
评估外源性表面活性物质治疗对细菌性肺炎婴儿死亡率和肺部并发症的影响。
我们采用Cochrane协作网的标准方法检索数据库。我们检索了Cochrane对照试验中心注册库(CENTRAL)(《Cochrane图书馆》2011年第6期);医学期刊数据库(MEDLINE)(通过Ovid SP检索2011年6月);荷兰医学文摘数据库(EMBASE)(通过Ovid SP检索1980年至2011年6月);以及护理学与健康领域数据库(CINAHL Plus)(通过EBSCOHost检索2011年6月)。
我们将检索范围限制在对胎龄>35周、出生后28天内患有细菌性肺炎的婴儿进行表面活性物质替代疗法的随机和半随机试验。主要结局指标为死亡、肺炎缓解时间、慢性肺病发病率、气胸和肺出血。
我们根据预定义的标准评估所有研究是否符合纳入条件。我们使用RevMan 5(RevMan 2011)提取数据。我们采用Cochrane协作网的标准方法进行数据收集和分析,以评估偏倚风险、异质性、治疗效果、缺失数据,并在适当情况下评估报告偏倚。
我们未找到任何符合纳入标准的研究。
随机对照试验(RCT)尚无证据支持或反驳表面活性物质对已证实或疑似患有细菌性肺炎的近足月和足月婴儿的疗效。仍需要进行RCT来回答这个问题。